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Abstract
The aim of this study was to evaluate the diagnostic performance of immunochromato-
graphic tests (ICTs) for the detection of Mycoplasma pneumoniae. Medline/Pubmed,
Embase, the Cochrane Library, and ISI Web of Science were searched through June 12,
2019 for relevant studies that used ICTs for the detection of M. pneumoniae infection with
polymerase chain reaction (PCR) or microbial culturing as reference standards. Pooled diag-
nostic accuracy with 95% confidence interval (CI) was calculated using a bivariate random
effects model. We also constructed summary receiver operating characteristic curves and
calculated the area under the curve (AUC). Statistical heterogeneity was evaluated by χ2 test
or Cochrane’s Q test. Thirteen studies including 2,235 samples were included in the meta-
analysis. The pooled sensitivity and specificity for diagnosing M. pneumoniae infection were
0.70 (95% CI: 0.59–0.79) and 0.92 (95% CI: 0.87–0.95), respectively. The positive likelihood
ratio (LR) was 8.94 (95% CI: 4.90–14.80), negative LR 0.33 (95% CI: 0.22–0.46), diagnostic
odds ratio 29.20 (95% CI: 10.70–64.20), and AUC 0.904. In subgroup analysis, ICTs demon-
strated similar pooled sensitivities and specificities in populations of children only and mixed
populations (children + adults). Specimens obtained from oropharyngeal swabs exhibited a
higher sensitivity and specificity than those of nasopharyngeal swab. Moreover, pooled esti-
mates of sensitivity and accuracy for studies using PCR as a reference standard were higher
than those using culture. The pooled sensitivity and specificity of Ribotest Mycoplasma®, the
commercial kit most commonly used in the included studies, were 0.66 and 0.89, respec-
tively. Overall, ICT is a rapid user-friendly method for diagnosing M. pneumoniae infection
with moderate sensitivity, high specificity, and high accuracy. This suggests that ICT may be
useful in the diagnostic workup of M. pneumoniae infection; however, additional studies are
needed for evaluating the potential impact of ICT in clinical practice.
Introduction
Mycoplasma pneumoniae is an important cause of respiratory tract infection (RTI) in school-
age children and young adults [1–4]. M. pneumoniae is responsible for approximately 10–40%
PLOS ONE
PLOS ONE | https://doi.org/10.1371/journal.pone.0230338 March 17, 2020 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Yoon SH, Min IK, Ahn JG (2020)
Immunochromatography for the diagnosis of
Mycoplasma pneumoniae infection: A systematic
review and meta-analysis. PLoS ONE 15(3):
e0230338. https://doi.org/10.1371/journal.
pone.0230338
Editor: Paulo Lee Ho, Instituto Butantan, BRAZIL
Received: January 7, 2020
Accepted: February 26, 2020
Published: March 17, 2020
Copyright: © 2020 Yoon et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
of community-acquired pneumonia (CAP) cases [3, 5], rising to 70% in closed populations
during epidemics [6–8]. M. pneumoniae infection is primarily known to present with a mild
clinical course [6]; however, 3–4% of those are reported to develop into fulminant pneumonia
with hypoxia [9, 10]. Extrapulmonary complications, primarily being central nervous system
complications, may also occur in approximately 25% of M. pneumoniae-infected individuals
[1, 11].
M. pneumoniae lacks a cell wall, and therefore, β-lactam antibiotics, which are active against
most respiratory bacterial pathogens for RTI in children, are ineffective against M. pneumoniae
[12]. A prompt and precise diagnosis of M. pneumoniae infection leads to the use of appropri-
ate antibiotics. However, it is difficult to distinguish M. pneumoniae from other causative
microorganisms of RTI early during the clinical course based on patient history, symptoms,
physical examination, or a chest radiograph. Therefore, laboratory confirmation of the micro-
organism is crucial for planning the appropriate management [13–16].
While microbial culturing has been a gold standard for M. pneumoniae diagnosis, M. pneu-
moniae are fastidious and cultivation may require weeks for growth. Therefore, culturing is
not routinely performed in clinical practice [17]. Serology is a more convenient and widely
used method than culturing. A single high titer of M. pneumoniae-specific antibody is indica-
tive of a recent infection; however, false-negative test results often occur early in the course of
illness [17, 18]. An increase in the M. pneumoniae-specific IgG titer� 4-fold during acute and
convalescent phases of the clinical course also implies recent infection [19]; however, this is
impractical in clinical practice as it requires 2–4 weeks of monitoring [17, 18]. ImmunoCard
Mycoplasma (Meridian Bioscience, Cincinnati, OH, USA), a 10-min card-based enzyme-
linked immunosorbent assay to detect M. pneumoniae IgM antibodies, has been developed
and is commercially available [20, 21]. However, ImmunoCard Mycoplasma is an assay for
IgM only and can exhibit false-positive results for an extended period of time after M. pneumo-
niae infection as M. pneumoniae IgM antibodies may persist for several months [21, 22]. Poly-
merase chain reaction (PCR) analysis is highly sensitive and currently used as a reference
diagnostic method for M. pneumoniae detection; however, it requires complex and time-con-
suming sample pretreatment, skilled technical ability, and expensive equipment [23, 24].
Recently, several techniques for the rapid diagnosis of M. pneumoniae have been developed,
including loop-mediated isothermal amplification (LAMP) [25, 26] and the immunochroma-
tographic test (ICT) [27–30]. LAMP is a technique in which DNA is amplified under isother-
mal conditions within one hour [31, 32]. Although LAMP shows high sensitivity and
specificity in the diagnosis of infectious diseases [33], it requires specific equipment for DNA
amplification. In addition, an isolated room and a closed reaction system are recommended
owing to unintended carryover contamination that may lead to false positives [34, 35]. There-
fore, LAMP is not thought to be practical for use in primary care settings [36, 37].
The immunochromatographic test (ICT), often referred to as a lateral-flow assay, is a popu-
lar application of enzyme-immunoassays that utilize antigen and antibody properties as a sam-
ple passes along a membrane [38–41]. ICT has several positive qualities, including that it is
simple and easy to perform, has a rapid assay time, exhibits long-term stability regardless of cli-
mate, is inexpensive, and is an instrument-free diagnostic test [42]. Moreover, results can be
observed with the naked eye within 10–15 min [28, 29, 43, 44]. Recently, the diagnosis of CAP
has been facilitated by the use of ICT-based urinary antigen tests for Streptococcus pneumoniae
and Legionella pneumophila serogroup-1 [45, 46]. ICT targeting of M. pneumoniae antigen
(e.g. ribosomal protein L7/L12) has also been developed and is commercially available [30, 36,
47–50]. However, the studies that have evaluated the performance characteristics of ICT for
the detection of M. pneumoniae have not currently been systematically reviewed or integrated.
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Therefore, the aim of this systematic review and meta-analysis was to integrate and assess the
evidence for the diagnostic accuracy of ICT for M. pneumoniae infection.
Materials and methods
This review was performed in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Statement (PRISMA) [51]. The protocol has been registered with
Prospero: International prospective register of systematic reviews (registration number
CRD42019140809).
Literature search
We searched on Medline/Pubmed, Embase, the Cochrane Library, and ISI Web of Science
using the keywords Mycoplasma pneumoniae, immunochromatography and lateral flow assay.
The search strategy included “Mycoplasma pneumoniae AND immunochromatography OR
lateral flow assay” (S1 Search strategy). The search was executed on June 12, 2019. Additional
studies were identified by examining the reference lists of the relevant articles. No language
restrictions were applied. As the current study was based on a systematic review of previously
published studies, institutional review board approval and patient consent were not necessary.
This research received no specific grant from any funding.
Eligibility criteria
Studies were considered eligible if they assessed the accuracy of ICT for the diagnosis of M.
pneumoniae infection and were detailed enough to allow the construction of a 2 × 2 table. We
defined ICT as any assay identifying M. pneumoniae antigens in human respiratory specimens
using ICT formats. Studies using PCR or microbial cultures as reference standards were eligi-
ble for inclusion in the current study. In vitro and in vivo animal studies were excluded. Edito-
rials, letters to the editors, and conference abstracts were also excluded.
Study selection and data extraction
Two reviewers (SHY and JGY) independently screened the titles and abstracts for potential rel-
evance and conducted full-text reviews of the selected publications. Any disagreements were
resolved by a third reviewer (IKM) following a discussion with all three reviewers. Author
names, country of origin for the study, publication year, study design, study period, age distri-
bution of the study population (children were defined as� 18 years of age), participant gender,
index test assay, index test target, index test company, reference standard, type of specimen,
sample size, and data regarding true positive, false positive, true negative, and false negative
were extracted. If studies consisted of multiple groups, each group was treated as a single
study. If there was insufficient information to construct the 2 × 2 table, we attempted to con-
tact the corresponding authors by e-mail.
Quality assessment
The validity of the included studies was assessed using the Quality Assessment of Diagnostic
Accuracy Studies 2 (QUADAS-2) tool [52]. QUADAS-2 evaluates the risk of bias and the
applicability of diagnostic accuracy studies, which consists of four key domains (patient selec-
tion, index test, reference standard, and flow and timing). Each domain was assessed in terms
of risk of bias and the first three domains with respect to concerns regarding applicability.
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Statistical analysis
Summary estimates of sensitivity and specificity along with 95% confidence intervals were cal-
culated based on a bivariate random effects model [53]. From the pooled estimates, we derived
the diagnostic odds ratio (DOR), positive LR, negative LR, and 95% CI [54].
Summary receiver operating characteristic (SROC) curves and the area under the curve
(AUC) obtained from the fitted bivariate random effects model were used to summarize the
overall test performance. SROC curves were plotted with the confidence region and prediction
region. Heterogeneity of sensitivity and specificity was assessed by visual inspection of forest
plots and by χ2 test analysis (p< 0.05 indicated significant heterogeneity). If heterogeneity
between studies existed, a bivariate random effects model was adopted [55–57]. A fixed value
(0.5) was added as a continuity correction to all cells for studies with zero values.
We planned subgroup analyses prior to starting the evaluations as heterogeneity among the
studies was expected. The following variables were expected to be possible sources of heteroge-
neity: age of the population (children, adult, mixed), type of index test and type of specimen,
reference standard used, and blinding procedures. Potential publication bias was visually
assessed using a funnel plot [58, 59]. The statistical significance of publication bias was tested
using the Egger’s test [60]. R package, version 3.6.0 (The R Foundation for Statistical Comput-
ing, Vienna, Austria), was used for all statistical analyses.
Results
Characteristics of the included studies
Totally, 66 articles were retrieved. After the removal of duplicate articles and exclusion of stud-
ies based on titles and abstracts, 13 articles remained for full text review. Four of the 13 studies
were excluded as two studies did not provide sufficient data for generation of a 2 × 2 contin-
gency table and the other two studies did not use PCR or microbial cultures as reference stan-
dards. Of the nine studies not excluded, several evaluated more than one reference method
[28] and different patient groups [48], brand of index test [36], and type of specimen [49].
Each dataset from these studies was considered separately. Therefore, 13 studies (11 in English,
1 in Korean, 1 Japanese) [28–30, 36, 47–50, 61] were ultimately included for quantitative data
synthesis and meta-analysis (Fig 1).
The data sets were extracted from the 13 articles and consisted of 2,235 samples. Descriptive
characteristics of the studies are summarized in Table 1. All the studies were conducted in
Asia (2 in China [29, 61], 10 in Japan [28, 30, 36, 47–49], and 1 in Korea [50]). Seven studies
(53.8%) included both adults and children [28, 36, 47, 48] while the remaining six studies
(46.2%) included only children [29, 30, 49, 50, 61]. No studies specifically evaluated adult pop-
ulations (� 18 years of age). Among the ICTs used in the studies included in our meta-analy-
sis, Ribotest Mycoplasma1 (Asahi Kasei Pharma Co., Tokyo, Japan) was the most frequently
assessed with eight (57.6%) of the studies evaluating this ICT [30, 36, 47–50]. PCR was used as
the reference standard in 11 (84.6%) of the studies [28–30, 36, 47–49, 61] and microbial cultur-
ing was used in two (15.4%) of the studies [28, 50]. No studies described the duration of symp-
toms prior to testing. The specific age ranges of enrolled patients and gender proportions are
summarized in S1 Table.
Quality assessment
Results of QUADAS-2 assessment for evaluating the quality of the studies are shown in Fig 2
and S2 Table. With respect to the risk of bias, in the patient selection domain, 61.5% of the
studies were considered “unclear” risk of bias as they failed to specify the methods used for
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Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart of the selection process used for eligible
studies.
https://doi.org/10.1371/journal.pone.0230338.g001
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Table 1. Characteristics of the studies included in the meta-analysis.
Year, Author Country Study
periods
Age Specimen Patients Index test assay Index test
target
Company Reference
standard
MP confirmed/
non-MP
confirmed (n)
2015, Li China Feb 2014
to Aug
2014
Children� OP swab +
sputum
pneumonia +
suspected MP
infection
Colloidal gold-
based IC assay
MP
membrane
protein P1
In-house ICT PCR 78/224
2015,
Miyashita
Japan Nov 2013
to Oct
2014
children +
adult
NP swab CAP Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 8/110
2015,
Yamazaki
Japan Sep 2012
to Mar
2013
children NP swab pneumonia or
bronchitis
Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 85/127
2016,
Miyashita-1
Japan May
2015 to
Aug 2015
children +
adult
NP swab RTI Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 46/355
2016,
Miyashita-2
Japan May
2015 to
Aug 2015
children +
adult
NP swab CAP Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 8/60
2016, Sano-1 Japan − children +
adult
pharyngeal
swab§
RTI Mycoplasma
RP-L7/L12 ICT
MP L7/L12
ribosomal
protein
In-house ICT PCR 33/143
2016, Sano-2 Japan − children +
adult
pharyngeal
swab§
RTI Mycoplasma
RP-L7/L12 ICT
MP L7/L12
ribosomal
protein
In-house ICT culture 35/141
2017,
Kakuya-1
Japan Dec 2015
to Aug
2016
children NP swab community-
acquired lower
RTI
Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 15/43
2017,
Kakuya-2
Japan Dec 2015
to Aug
2016
children OP swab community-
acquired lower
RTI
Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 15/43
2017, Song China Dec 2016
to Jan
2017
children OP swab pneumonia SWCNT/CGIC
strip
MP
membrane
protein P1
In-house ICT PCR 97/40
2018,
Namkoong-1
Japan Dec 2015
to Dec
2016
children +
adult
OP swab clinically
suspected MP
infection
SAI system¶ MP antigen Mizuho Medy,
Saga, Japan or
Fujifilm,
Kanagawa, Japan
PCR 73/84
2018,
Namkoong-2
Japan Dec 2015
to Dec
2016
children +
adult
OP swab clinically
suspected MP
infection
Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
PCR 73/84
2019, Yang Korea Aug 2010
to Aug
2018
children NP aspirates lower RTI Ribotest
Mycoplasma1
MP L7/L12
ribosomal
protein
Asahi Kasei
Pharma, Tokyo,
Japan
culture 119/96
CAP, community acquired pneumonia; MP, Mycoplasma pneumoniae; PCR, polymerase chain reaction; RTI, respiratory tract infection; SWCNT/CGIC, single-walled
carbon nanotubes coupled with the colloidal gold-monoclonal antibody immunochromatographic strips; ICT, immunochromatographic test; NP, naso-pharyngeal; OP,
oropharyngeal; SAI, silver amplification immunochromatography
−: Not given.
� Children and adults were defined as younger and older than 18 years of age, respectively.
§ Authors did not provide details regarding the source of the swabs (nasopharyngeal or oropharyngeal).
¶ The SAI system consists of a Quick Chaser1 Auto Myco (Mizuho Medy, Saga, Japan) or FUJI DRI-CHEM IMMUNO AG
Cartridge Myco (Fujifilm, Kanagawa, Japan) combined with an analyzer Quick Chaser Immuno Reader (Mizuho Medy,
Saga, Japan) or FUJI DRI-CHEM IMMUNO AG1 (Fujifilm, Kanagawa, Japan).
https://doi.org/10.1371/journal.pone.0230338.t001
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enrollment of the patients, whether consecutive or random. The remaining studies were classi-
fied as “low” risk of bias. In the index test domain, most of the studies (76.9%) were classified
as “unclear” risk of bias since the authors did not report the index test, did not clarify whether
the ICT results were identified without knowledge of the results of the reference standard [62,
63]. However, if index test results were interpreted with dedicated ICT readers, the studies
were judged to be at low risk of bias. In the reference standard domain, all studies were at
“low” risk of bias because PCR and culturing were regarded as being objective methods,
regardless of whether they were interpreted without knowledge of the index test results. In the
flow and timing domain, most studies (12/13, 92.3%) were at “low” risk of bias. Applicability
was of low concern for all the studies in the index and reference standard domain. The patient
selection domain was assessed to be an “unclear” concern for seven of the studies (53.8%) as
they enrolled only lower RTI patients.
Overall accuracy of IC
The sensitivity and specificity of each study included in the analysis are shown in the form of a
forest plot in Fig 3. Significant heterogeneity between studies was noted in terms of sensitivity
(χ2 = 63.75; p< 0.0001) and specificity (χ2 = 60.62; p< 0.0001). Taking into account the statis-
tical heterogeneity, a meta-analysis was performed using a bivariate random effects model.
Funnel plot asymmetry (p = 0.0001 from Egger’s test) revealed the existence of publication
bias among the included studies (S1 Fig).
The overall sensitivity of the studies included in the analysis was estimated from the bivari-
ate random effects model to be 0.70 (95% CI; 0.59–0.79). Similarly, the overall specificity was
estimated to be 0.92 (95% CI; 0.87–0.95). DOR, as shown in Table 2, was 29.20 (95% CI;
10.70–64.20). The AUC for the SROC was 0.904 (Fig 4).
Subgroup analysis
According to our covariate significance test using a bivariate random effects model, the index
test assay was the only significant heterogeneity factor (S3 Table). However, because subgroup
analysis may be valuable based on the clinical characteristics, we conducted subgroup analysis
to identify each potential source of heterogeneity. The summary estimates for the different
subgroups are presented in Table 3.
ICT showed similar pooled sensitivity and specificity in populations of children and mixed
populations (children + adults). The specimens obtained from oropharyngeal swabs showed a
Fig 2. Quality assessment of the diagnostic accuracy studies-2 (QUADAS-2).
https://doi.org/10.1371/journal.pone.0230338.g002
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Fig 3. Coupled forest plots of the sensitivity and specificity of immunochromatographic tests for diagnosing
Mycoplasma pneumoniae infection. The studies are indicated by year and author name. The numbers are pooled
estimates with 95% confidence interval (CI) in brackets. Horizontal lines indicate 95% CIs.
https://doi.org/10.1371/journal.pone.0230338.g003
Table 2. Summary estimates of the diagnostic accuracy of immunochromatographic tests used to diagnose Mycoplasma pneumoniae.
References
(year and author)
Sensitivity (95% CI) Specificity (95% CI) +LR (95% CI) −LR (95% CI) DOR (95% CI)
2015 Li 0.97 (0.90–0.99) 1.00 (0.98–1.00) 435.76 (27.33–6947.27) 0.03 (0.01–0.11) 13739.40 (652.36–289,367.43)
2015 Miyashita 0.61 (0.31–0.85) 0.91 (0.84–0.95) 6.46 (2.97–14.04) 0.43 (0.19–0.98) 15.04 (3.41–66.29)
2015 Yamazaki 0.74 (0.64–0.82) 0.81 (0.73–0.87) 3.86 (2.64–5.63) 0.32 (0.22–0.47) 11.92 (6.21–22.88)
2016 Miyashita -1 0.71 (0.57–0.82) 0.90 (0.86–0.92) 6.95 (4.87–9.93) 0.32 (0.20–0.50) 21.72 (10.59–44.57)
2016 Miyashita -2 0.61 (0.31–0.85) 0.88 (0.77–0.94) 4.97 (2.13–11.62) 0.44 (0.19–1.01) 11.21 (2.40–52.43)
2016 Sano -1 0.57 (0.41–0.72) 0.91 (0.86–0.95) 6.61 (3.61–12.09) 0.47 (0.32–0.69) 14.15 (5.79–34.57)
2016 Sano -2 0.57 (0.41–0.72) 0.92 (0.86–0.95) 7.03 (3.77–13.11) 0.47 (0.32–0.68) 15.01 (6.14–36.68)
2017 Kakuya -1 0.34 (0.16–0.59) 0.81 (0.67–0.90) 1.78 (0.72–4.41) 0.81 (0.55–1.19) 2.19 (0.61–7.83)
2017 Kakuya -2 0.66 (0.41–0.84) 0.90 (0.77–0.96) 6.42 (2.50–16.50) 0.38 (0.19–0.76) 16.76 (4.05–69.30)
2017 Song 0.72 (0.62–0.80) 0.99 (0.89–1.00) 58.99 (3.74–929.82) 0.28 (0.21–0.39) 207.65 (12.33–3,495.88)
2018 Namkoong -1 0.90 (0.81–0.95) 0.99 (0.95–1.00) 152.77 (9.62–2,425.12) 0.10 (0.05–0.20) 1498.47 (84.06–26,712.36)
2018 Namkoong -2 0.64 (0.53–0.74) 0.90 (0.82–0.95) 6.42 (3.32–12.42) 0.40 (0.29–0.54) 16.13 (6.87–37.87)
2019 Yang 0.62 (0.53–0.70) 0.95 (0.89–0.98) 13.38 (5.37–33.35) 0.40 (0.31–0.50) 33.66 (12.19–92.92)
Summary estimates 0.70 (0.59–0.79) 0.92 (0.87–0.95) 8.94 (4.90–14.80) 0.33 (0.22–0.46) 29.20 (10.70–64.20)
CI, confidence interval; +LR, positive likelihood ratio, −LR, negative likelihood ratio, DOR, diagnostic odds ratio
https://doi.org/10.1371/journal.pone.0230338.t002
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Fig 4. Summary receiver operating characteristic (SROC) curves of the diagnostic accuracy of
immunochromatographic tests (ICTs) for Mycoplasma pneumoniae infection. Summary points of the sensitivity
and specificity, SROC curve, 95% confidence region, and 95% prediction region are shown. The area under the curve
of the SROC curve for ICT was 0.904.
https://doi.org/10.1371/journal.pone.0230338.g004
Table 3. Subgroup analyses: Summary estimates using a bivariate random effects model.
Variables Sensitivity Specificity +LR −LR DOR AUC§
Population
Children� (n = 6) 0.72 (0.49–0.87) 0.94 (0.80–0.98) 15.40 (2.93–45.20) 0.32 (0.13–0.59) 70.80 (5.19–285.00) 0.911
Mixed (children + adult) (n = 7) 0.68 (0.56–0.78) 0.91 (0.88–0.92) 7.12 (5.48–8.98) 0.36 (0.24–0.49) 20.80 (11.60–34.50) 0.906
Type of specimen
Nasopharyngeal swab (n = 5) 0.64 (0.48–0.77) 0.87 (0.82–0.91) 4.92 (3.24–7.03) 0.42 (0.26–0.60) 12.50 (5.57–24.50) 0.866
Oropharyngeal swab (n = 4) 0.74 (0.58–0.86) 0.96 (0.84–0.99) 21.50 (3.98–64.80) 0.29 (0.15–0.47) 98.60 (8.84–371.00) 0.907
Reference standard
PCR (n = 11) 0.72 (0.59–0.82) 0.92 (0.86–0.95) 8.88 (4.52–15.10) 0.31 (0.20–0.46) 31.80 (10.50–73.20) 0.908
Culture (n = 2) 0.61 (0.52–0.69) 0.94 (0.89–0.97) 10.20 (5.13–18.30) 0.43 (0.34–0.52) 24.70 (10.70–46.90) 0.763
Index test assay
Ribotest Mycoplasma1 (n = 8) 0.66 (0.60–0.71) 0.89 (0.85–0.92) 6.00 (4.55–7.88) 0.39 (0.33–0.45) 15.70 (11.00–21.40) 0.786
Others (n = 5) 0.79 (0.55–0.92) 0.98 (0.91–1.00) 49.20 (6.61–157.00) 0.23 (0.08–0.47) 378.00 (14.40–1750.00) 0.962
Numbers are pooled estimates with 95% confidence intervals (CI) in parentheses. Horizontal lines indicate 95% CIs.
+LR, positive likelihood ratio,
−LR, negative likelihood ratio, DOR, diagnostic odds ratio; AUC, area under the summary receiver operating characteristic curve.
�Children and adults were defined as younger and older than 18 years of age, respectively.
§ The area under the summary receiver operating characteristic curve was obtained from a fitted bivariate random effects model and used to summarize overall test
performance.
https://doi.org/10.1371/journal.pone.0230338.t003
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higher sensitivity and specificity than those from nasopharyngeal swabs. In addition, the
pooled estimates of sensitivity and accuracy for studies using PCR reference standards were
higher than those using microbial culturing (Table 3).
Among the 13 studies included in our current analysis, eight of the studies consisting of
1,287 samples used the Ribotest Mycoplasma1 brand of ICT [30, 36, 47–50]. The pooled sensi-
tivity, specificity, positive LR, negative LR, and DOR of Ribotest Mycoplasma1 for M. pneu-
moniae infection were 0.66 (95% CI, 0.60–0.71), 0.89 (95% CI, 0.85–0.92), 6.00 (95% CI, 4.55–
7.88), 0.39 (95% CI, 0.33–0.45) and 15.70 (95% CI, 11.00–21.40), respectively (S4 Table). The
overall accuracy of Ribotest Mycoplasma1 was 0.786 (S2 Fig). As only one study provided
information regarding blinding prior to testing, we were unable to conduct subgroup analysis.
Discussion
The current systematic review and meta-analysis is the first to establish an overview of the
diagnostic accuracy of ICT for M. pneumoniae infection. ICT showed high specificity (0.92),
with modest sensitivity (0.70) for the diagnosis of M. pneumoniae infection. The SROC AUC
was 0.904, which indicates that ICT was highly accurate in the diagnosis of M. pneumoniae
infection. This means that if a test result was positive, it was unlikely to be a false-positive result
[64]. Therefore, physicians can confidently make a diagnosis of M. pneumoniae infection for a
patient with respiratory symptoms and a positive ICT result and can then start proper antibi-
otic treatment to control the infection. Unfortunately, negative ICT results cannot be used to
definitely rule out M. pneumoniae infection [64]. Therefore, the diagnosis should be confirmed
using other laboratory methods if the test result can influence management decisions of
patients.
Regardless, the easy-to-perform, rapid, accurate diagnosis of M. pneumoniae infection
using ICT has the potential to decrease disease burden by the early prevention of outbreaks in
closed populations, such as schools, colleges, and nursing home [5, 65]. ICT may also be a use-
ful test during epidemic outbreaks, even in environments such as private hospitals that may
not have specialized laboratories or emergency rooms required for making quick diagnoses. In
addition, M. pneumoniae infection can cause significant morbidity, and even mortality, in
patients of extreme age [5]. Prompt diagnosis and treatment of M. pneumoniae infection in
these patients may be specifically beneficial.
Moreover, the prevalence of macrolide-resistant M. pneumoniae (MRMP) has recently
increased worldwide, reaching prevalence rates up to 80–90%, especially in Asian countries
[66–70]. MRMP is associated with severe clinical course (e.g., longer durations of fever, cough,
and hospital stays) and more extrapulmonary complications [69, 71]. As macrolides are dra-
matically less effective against MRMP than against macrolide-sensitive M. pneumoniae, alter-
native antibiotic treatment including tetracyclines or fluoroquinolones is warranted in severe
cases [12, 70–73]. Although ICT is not able to identify whether a particular strain of M. pneu-
moniae is resistant to macrolide or not, until additional genetic testing for MRMP strains
become available, rapid M. pneumoniae diagnosis can provide a clinical basis for the use of
alternative antibiotics when no clinical improvement is observed with the use of macrolides as
the first line of antibiotics [74].
As for the target age group, our study demonstrated that the diagnostic accuracy of ICT
for M. pneumoniae infection was similar between the groups containing both adults and chil-
dren and the groups containing only children. This finding suggests that ICT may be used
regardless of patient age. Nevertheless, clinical studies evaluating ICT focusing on adult popu-
lations and studies that compare the accuracy of ICT between children and adults are still
warranted.
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The only significant heterogeneity factor in our covariate significance analysis was the
index test used. The majority of index tests used in the studies analyzed was the commercially
available Ribotest Mycoplasma1 kit. Pooled estimates of the sensitivities, specificities, and
AUC for Ribotest Mycoplasma1 was lower than that of other index tests. The other commer-
cial ICT kits used included the FUJI DRI-CHEM IMMUNO AG Cartridge Myco (Fujifilm,
Kanagawa, Japan) and the Quick Chaser1 Auto Myco M. pneumoniae antigen detection kit
(Mizuho Medy, Saga, Japan), which uses silver amplification. These have been shown to
exhibit high sensitivity and specificity (0.904 and 1.0, respectively), even surpassing Ribotest
Mycoplasma1 (0.644 and 0.905, respectively) in head-to-head comparisons [36]. Test results
derived from commercial kits would be more concern for clinicians in the practical use, but
there remains a lack of research evaluating the head-to-head performance of ICTs across com-
mercial brands.
The best sampling site for detecting M. pneumoniae, whether OP swabs or NP swabs,
remains controversial [75–77]. In our meta-analysis, higher sensitivity and specificity were
found for OP swabs. However, our findings were limited since head-to-head comparisons
were not performed in most of the studies included in our analyses. Only one study reported
that using OP swab specimens for ICT analysis showed higher accuracy in detecting lower
RTIs caused by of M. pneumoniae than that of NP swab specimens when the samples were
concomitantly obtained [49]. The authors suspected the reasons for their findings was due to
varied M. pneumoniae density in the NP swab specimens, which were collected in a blinded
fashion, and the larger OP swab tip, which was able to reach deeper into the airway resulting
in a specimen higher load of M. pneumoniae. In addition, it has been reported that a higher
copy number of M. pneumoniae is found in the alveoli than on the epithelium of the upper
respiratory tract [78, 79].
Microbial culturing and PCR are currently the most commonly used reference standards
for M. pneumoniae diagnosis. M. pneumoniae culturing has specific short-comings, including
being less sensitive, difficult to perform, and requiring longer than PCR to obtain results [17,
80–84]. In our current analysis, the overall sensitivity and accuracy of ICT using PCR as the
reference standard were higher than of ICT using microbial culturing, but the overall specific-
ity was similar. Accordingly, we suggest that PCR is a more useful reference standard for ICT
because of the moderate pooled sensitivity of ICT.
It is noteworthy that our current study had several limitations. First, there were no studies
included that assessed the difference in ICT performance between macrolide-sensitive and
macrolide-resistant M. pneumoniae strains. In addition, industrial sponsorship, inclusion/
exclusion of comorbid conditions, duration of clinical symptoms prior to testing, time lapse
before specimen processing, and blinded assessment of ICT were so rarely reported that we
were not able to evaluate their effects.
Conclusions
ICT is a rapid and easy-to-use detection method with moderate sensitivity, high specificity,
and high accuracy in diagnosing M. pneumoniae infection, regardless of patient age. This sug-
gests that ICT is a useful test during the diagnostic workup of RTIs. Major practical advantages
of ICT are its user-friendly format and short time requirements (usually� 20 minutes). ICT
could function as the point-of-care in clinical practice, instead of serology, PCR and microbial
culturing, especially in resource-limited settings. If physicians are aware of the limitations of
ICT, such as false negative results, they could make educated decisions in using ICT to imple-
ment appropriate antibiotics stewardship and infection control as well as to help make
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decision regarding the use of other diagnostic modalities. However, additional studies regard-
ing the potential impact of ICT in clinical practice are necessary. These include the cost-effec-
tiveness of routine ICT use and whether ICT may allow for decreases in additional diagnostic
tests and result in reducing the excessive use of macrolides.
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